Mousquetaires: Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors
Study Details
Study Description
Brief Summary
This observational study compared quality of histological sampling of pancreatic EUS-FNB with the 20-gauge Procore® and 22-gauge Acquire® needles. In total, 68 patients were recruited. Histological diagnosis was achieved and a histological core biopsy was obtained in 82% of patients (28/34) in the 20-gauge Procore® group and 97% of patients (33/34) in the 22-gauge Acquire® group (P=0.1). Core biopsy specimens obtained were significantly longer with the 22-gauge Acquire® needle with a mean cumulative length of tissue core biopsies per needle pass of 4,33±3,46mm vs. 7,9±4,35mm for the 20-gauge Procore® (P<0,01). Reproducibility of this simple histological criterion was validated in intra and inter-observer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission: 34 punctures were performed with a 20-gauge Procore®, and 34 with a 22-gauge Acquire®. Histological material was studied in a blinded manner with respect to the needle, and cumulative length of tissue core biopsies per needle pass was determined. Intra and inter-observer variability of this criterion was then evaluated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 20-gauge Procore® Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission: 34 punctures were performed with a 20-gauge Procore® during the period study |
Procedure: EUS-FNB with 20-gauge Procore® needle
Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
|
| 22-gauge Acquire® Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission: 34 punctures were performed with a 22-gauge Acquire® during the period study |
Procedure: EUS-FNB with 22-gauge Acquire® needle
Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
|
Outcome Measures
Primary Outcome Measures
- pancreatic mass anatomopathological characterization [in the 7 days after procedure]
pancreatic mass anatomopathological characterization, presence of histological sampling and cumulative length of tissue core biopsies per needle pass.
Eligibility Criteria
Criteria
Inclusion Criteria:
- All consecutive patients ≥18 who were referred for EUS-FNB for solid pancreatic or peripancreatic mass were included
Exclusion Criteria:
-
non-accessible pancreatic mass because of history of Billroth II or Roux-en-Y reconstruction
-
coagulation disorders (such as partial thromboplastin time >42 seconds, prothrombin time [Quick value] <50%, platelet count <50 000/mm³), treatment with clopidogrel, pregnancy.
-
patients <18 years of age
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Clinique PARIS-BERCY | Charenton-le-Pont | France | 94220 |
Sponsors and Collaborators
- Société Française d'Endoscopie Digestive
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Mousquetaires